Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Systemic therapy for older women with breast cancer
Autore:
Kimmick, GG; Muss, HB;
Indirizzi:
Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA Wake Forest Univ Winston Salem NC USA 27157 , Winston Salem, NC 27157 USA Univ Vermont, Burlington, VT USA Univ Vermont Burlington VT USAUniv Vermont, Burlington, VT USA
Titolo Testata:
ONCOLOGY-NEW YORK
fascicolo: 3, volume: 15, anno: 2001,
pagine: 280 - 291
SICI:
0890-9091(200103)15:3<280:STFOWW>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
SURGICAL-ADJUVANT-BREAST; COOPERATIVE-ONCOLOGY-GROUP; CONGESTIVE-HEART-FAILURE; BOWEL-PROJECT P-1; ELDERLY PATIENTS; RANDOMIZED TRIAL; CLINICAL-TRIALS; FIRST-LINE; COMBINATION CHEMOTHERAPY; POSTMENOPAUSAL WOMEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
76
Recensione:
Indirizzi per estratti:
Indirizzo: Kimmick, GG Wake Forest Univ, Ctr Comprehens Canc, Med Ctr Blvd, Winston Salem, NC 27157 USA Wake Forest Univ Med Ctr Blvd Winston Salem NC USA 271577 USA
Citazione:
G.G. Kimmick e H.B. Muss, "Systemic therapy for older women with breast cancer", ONCOLOGY-NY, 15(3), 2001, pp. 280-291

Abstract

Breast cancer is a common problem in older women. As the number of medicalillnesses increases with age and the life expectancy decreases, the benefits of systemic therapy for women with breast cancer become questionable. All women over age 65 years are at high enough risk of breast cancer to consider the risk/benefit ratio of preventive therapy with tamoxifen (Nolvadex) or participation in the Study of Tamoxifen and Raloxifene (STAR) trial. Adjuvant chemotherapy and hormonal therapies for early breast cancer significantly improve disease-free and overall survival; recommendations for their use are based on risk of tumor recurrence. Use of tamoxifen in the adjuvant setting in women with receptor-positive tumors is a relatively simple decision in light of its favorable toxicity profile, The delivery of adjuvant chemotherapy is a more complicated decision, and the patient's wishes, estimated life expectancy, presence of comorbid conditions, and estimated benefitfrom treatment should be considered. The primary goal of the treatment of metastatic breast cancer is palliation, We discuss trials specific to olderwomen and make appropriate treatment recommendations. Unfortunately, thereis a paucity of data from clinical trials in women over age 70 years, However, because the clinical trial is the primary scientific mechanism for testing the efficacy of a treatment, every effort should be made to enter older women into treatment protocols.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/05/20 alle ore 15:43:42